NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its quarterly earnings results on Wednesday, February, 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.07. The biotechnology company earned $29.46 million during the quarter, compared to analyst estimates of $36.63 million. Arrowhead Pharmaceuticals had a net margin of 32.56% and a return on equity of 18.21%. View Arrowhead Pharmaceuticals' Earnings History.

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Arrowhead Pharmaceuticals.

9 brokers have issued 12-month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $32.00 to $83.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $64.13 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arrowhead Pharmaceuticals.

Press coverage about ARWR stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals saw a decrease in short interest in January. As of January 15th, there was short interest totalling 11,120,000 shares, a decrease of 8.9% from the December 31st total of 12,200,000 shares. Based on an average trading volume of 2,270,000 shares, the short-interest ratio is presently 4.9 days. Currently, 12.0% of the company's stock are sold short. View Arrowhead Pharmaceuticals' Current Options Chain.

Some companies that are related to Arrowhead Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ) and Perrigo (PRGO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Bank of America (BAC) and Bristol-Myers Squibb (BMY).

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.06%), FMR LLC (1.85%), Fiera Capital Corp (1.34%), Bank of New York Mellon Corp (1.05%), Goldman Sachs Group Inc. (0.86%) and Renaissance Technologies LLC (0.71%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Candriam Luxembourg S.C.A., Principal Financial Group Inc., Rafferty Asset Management LLC, Goldman Sachs Group Inc., Oak Ridge Investments LLC and Fiera Capital Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry and Patrick O'brien. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., FMR LLC, Credit Suisse AG, American International Group Inc., Mutual of America Capital Management LLC, Retirement Systems of Alabama, Man Group plc and Alliancebernstein L.P.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $40.50.

Arrowhead Pharmaceuticals has a market capitalization of $4.12 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]